26 Jun 2018
We are pleased to share an update from ReveraGen about its Vamorolone clinical trial. Vamorolone is an alternative treatment to existing steroids that aims to maximise the benefits while reducing the side effects. In 2014, The Duchenne Research Fund helped fund the...
25 Jun 2018
Five years ago we identified gene therapy as a viable treatment for Duchenne. Today we are reflecting on the exciting and inspiring events of the past week in the gene therapy arena which are now bringing hope and cautious optimism to the Duchenne community. We have...
18 Jun 2018
Message from Solid Biosciences: “We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD, our clinical trial investigating SGT-001 as a potential treatment for Duchenne muscular dystrophy (DMD). SGT-001 is a microdystrophin gene...
2 Feb 2018
The Duchenne Research Fund recently shared the news that we are supporting the KineDMD study – Dr Aldo Faisal’s ground-breaking artificial intelligence study at Imperial College London, in collaboration with Great Ormond Street Hospital, which aims to...
28 Sep 2017
On Wednesday 27 September 2017, the newly refurbished paediatric area in the Clinical Research Facility at Newcastle Royal Victoria Infirmary was officially opened by Professor Mark Walker and Dr Michela Guglieri. The refurbishment was possible thanks to the generous...
20 Sep 2017
The Duchenne Research Fund was delighted to participate in the Duchenne Hub information day held on 18 September 2017 at Alder Hey Children’s Hospital in Liverpool. The event was hosted by Duchenne UK, organised in conjunction with Hub manager Emma Heslop and the...
1 Sep 2017
Solid Biosciences recently reported that it has raised up to $50 million which will enable the biotech to continue to advance its programs for Duchenne muscular dystrophy, including development of a microdystrophin gene. We are forever grateful to our incredible...
11 Jul 2017
The Duchenne Research Fund’s supporters raised a spectacular £140,000 on their Yorkshire Three Peaks challenge. On Sunday 9th July 2017, 43 intrepid hikers from London, Manchester and New York donned their walking boots and waterproofs and braved the challenging...
24 Mar 2017
We’re pleased to share news from ReveraGen, the company developing the novel steroid alternative Vamorolone (previously called VBP15), that their drug has received Fast Track designation from the FDA, which will speed up the review of Vamorolone. In 2014, Duchenne...
28 Feb 2017
On #RareDiseaseDay, the Duchenne Research Fund is delighted to share the details of the exciting new projects we are funding thanks to donors’ generosity and support. Therapeutic developments for Duchenne muscular dystrophy have accelerated significantly in...